N Imperiali
Overview
Explore the profile of N Imperiali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laham G, Scuteri R, Cornicelli P, Arriola M, Raffaele P, Davalos Michel M, et al.
Transplant Proc
. 2016 Oct;
48(8):2650-2655.
PMID: 27788796
Background: The use of expanded criteria donor (ECD) kidneys has increased the overall availability of renal transplants. This study assessed the use of sirolimus in patients receiving Argentina-ECD kidneys. Methods:...
2.
Variances in the Use of Everolimus in Kidney Transplantation: A 2-Year Registry of Everyday Practice
Cicora F, Massari P, Acosta F, Petrone H, Cambariere R, Imperiali N, et al.
Transplant Proc
. 2015 Dec;
47(10):2841-5.
PMID: 26707299
Background: Everolimus (EVL)-based immunosuppressive strategies may permit the reduction of calcineurin inhibitors (CNI) and their side effects, while offering a safe and efficient treatment. Our aim was to describe our...
3.
First epidemiologic study in Argentina of the prevalence of BK viruria in kidney transplant patients
Schiavelli R, Bonaventura R, Rial M, Petrone H, Soler Pujol G, Gaite L, et al.
Transplant Proc
. 2014 Nov;
46(9):3010-4.
PMID: 25420812
Background: The worldwide seroprevalence of human BK polyomavirus (BKV) in adults is 80%. About 10%-60% of renal transplant recipients experience BKV infection, nephropathy of the graft may occur in 5%...
4.
Cicora F, Massari P, Acosta F, Petrone H, Cambariere R, Gonzalez I, et al.
Transplant Proc
. 2014 Nov;
46(9):2991-5.
PMID: 25420808
Proliferation signal inhibitors, such as everolimus, offer immunosuppression without the toxicity of calcineurin inhibitors. This descriptive and prospective study reports outcomes at 1 year and predictors of improved estimated glomerular...
5.
Farinelli P, Padin J, Troncoso J, Bertolotti A, Lenz M, Sanchez N, et al.
Transplant Proc
. 2014 Aug;
46(6):2090-5.
PMID: 25131114
Background: The development of intestinal transplant (Tx) programs introduces thymoglobulin donor treatment as well as an almost complete warm dissection of the abdominal organs to allocate them to different recipients....
6.
Mombelli C, Giordani M, Imperiali N, Bedini M, Luxardo R, Heredia A, et al.
Transplant Proc
. 2013 Jun;
45(4):1635-8.
PMID: 23726637
Background: Proteinuria (P) is a early sign of inflammation and renal damage. It has an important role in the detection, diagnosis, and monitoring of renal disease in transplanted patients. The...
7.
Larriba J, Imperiali N, Groppa R, Giordani C, Algranatti S, Redal M
Transplant Proc
. 2010 Feb;
42(1):257-9.
PMID: 20172323
The tacrolimus is metabolized primarily by CYP3A5, a member of the single nucleotide polymorphism family. It shows cytochrome P450 (SNP) in intron 3, which consists of a change of base,...
8.
Musso C, Enz P, Guelman R, Mombelli C, Imperiali N, Plantalech L, et al.
Perit Dial Int
. 2006 Oct;
26(6):717-8.
PMID: 17047243
No abstract available.
9.
Ventura A, Imperiali N, Dominguez-Gil B, del Prado Sierra M, Munoz M, Andres A, et al.
Transplant Proc
. 2003 Sep;
35(3):1078-80.
PMID: 12947865
No abstract available.
10.
Galimberti R, Parra I, Imperiali N, Rosa Diez G, Kowalczuk A, Algranati L, et al.
Int J Dermatol
. 2000 Jan;
38(12):918-20.
PMID: 10632772
No abstract available.